ESR1 and breast carcinoma: Several preclinical studies suggest that EPA/DHA supplementation may be most optimal for prevention of estrogen receptor-positive breast cancer when used with another chemoprevention agent such as vitamin D [41], a selective estrogen receptor modulator [43], or celecoxib [42].